Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 alone or with enfortumab vedotin in locally advanced or metastatic urothelial cancer
NL-OMON61183Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of PF-08634404 in transitional cell carcinoma (TCC), sponsored by Pfizer. Planned start May 2026; status: not yet recruiting.
02
Drugs
PF-08634404
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NL-OMON61183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61183.